Raleigh, NC, September 13, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, today introduced ClinCHAT, a co-developed AI-powered chatbot.
The product launch follows the announcement of ProPharma and H1's partnership in May to optimize research and development with the inclusion of AI, data insights, and analytics. ClinCHAT is the first product from this partnership and a major advance in surfacing R&D and product insights from massive data sets to optimize and de-risk clinical research.
Through AI, ClinCHAT utilizes the latest natural language processing (NLP) and machine learning algorithms to provide a frictionless experience for users navigating complex data queries, regardless of size or development stage. The new tool gives ProPharma seamless access to H1's real world and clinical trial performance data – which includes a database of some 340 million patients, 10 million physicians and over 420,000 clinical trials – to increase confidence and overall success in clinical research.
"ClinCHAT and our continued partnership with H1 reflects ProPharma's AI-first strategy and showcases our technology-enabled Research Consulting Organization business model," said ProPharma's Chief Strategy Officer and Head of Corporate Development, Bryan Katz. "ClinCHAT is an important tool for those innovators looking to de-risk decision making and accelerate the delivery of their programs with a higher probability of success."
ProPharma is committed to improving clinical trial access through innovation. The introduction of ClinCHAT follows the launch of ProPharma's Research Consulting Organization (RCO) model, a new type of research consulting and clinical service for biotech, pharma and device innovators to deliver bespoke solutions that bring life-saving drugs to market sooner and more cost effectively.
